Five little-known diseases to watch out for in 2017

The phrase “emerging disease”, to describe an infectious disease that is new to humans or which is suddenly increasing its geographical range or number of cases, dates back to the 1960s. But it was the realisation in the late 1970s and early 1980s that the world was in the throes of previously unrecognised pandemics of genital herpes and AIDS, that really propelled the term into the mainstream. The causative agent of genital herpes was type 2 herpes simplex virus (HSV-2), a pathogen that was reasonably well-known at the time, but whose capacity for explosive spread had been underestimated. AIDS, on the other hand, was a completely new infectious agent – one which we now know had been spreadi

Featured Posts
Recent Posts
Archive
Search By Tags
Follow Us
  • Facebook Basic Square
  • Twitter Basic Square
  • Google+ Basic Square

 Impavido® (miltefosine) is an FDA-approved treatment for cutaneous,  mucosal and visceral leishmaniasis in patients 12 years of age and older. PLEASE SEE FULL PRESCRIBING INFO 

®

Contact Your Doctor or the CDC to Learn More about IMPAVIDO (miltefosine)

Impavido is a registered trademark of Knight Therapeutics Licensed exclusively to Profounda in the USA

© 2015 Profounda, Inc. 

For Emergencies
Call 911